Credit: Shutterstock photoRoka Bioscience, which develops highly-automated molecular diagnostic testing systems for the detection of foodborne pathogens, raised $60 million by offering 5 million shares at $12, below the $14-$16 range. At its offer price, Roka now commands a market cap of $217 million and an enterprise value of $158 million. Roka Bioscience will list on the NASDAQ under the symbol ROKA. BofA Merrill Lynch, Leerink Partners, Cowen & Company and Wedbush PacGrow acted as joint bookrunners on the deal.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
